SCHEMBL14320671

SCHEMBL14320671

COc1cccc(-c2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3[nH]ncc3n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.57
SYK P43405 5/20 0.57
BRD4 O60885 3/20 0.53
MAPKAPK2 P49137 1/20 0.52
HTR2A P28223 3/20 0.50
HTR2C P28335 3/20 0.50
USP2 O75604 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
AURKA O14965 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320593 0.91 SYK (0.59) JAK2SYKHTR2AHTR2CUSP2
SCHEMBL14320440 0.89 JAK2 (0.55) JAK2SYKBRD4HTR2AHTR2C
SCHEMBL14320482 0.88 SYK (0.68) JAK2SYKHTR2AHTR2C
SCHEMBL14320378 0.87 BRD4 (0.54) JAK2SYKBRD4NPC1POLB
SCHEMBL14320515 0.87 SYK (0.52) JAK2SYKBRD4CLK4
SCHEMBL14320583 0.87 JAK2 (0.62) JAK2SYKHTR2AHTR2CMAPK1
SCHEMBL14320345 0.86 SYK (0.47) JAK2SYKBRD4MAPKAPK2
SCHEMBL14320601 0.86 JAK2 (0.49) JAK2SYKHTR2AHTR2CCLK4
SCHEMBL14320318 0.86 JAK2 (0.49) JAK2SYKCLK4AURKAEGFR
SCHEMBL14320267 0.86 SYK (0.57) JAK2SYKMAPK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK JAK2 60/4885SYK 11/4885BRD4 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.